Therapy with bendamustine previous to CAR T-cell remedy in sufferers with refractory giant B-cell lymphoma associates with poorer therapy outcomes, finds a latest examine.
Led by investigators of the Vall d’Hebron Institute of Oncology’s (VHIO) Experimental Hematology Group and the Superior Therapies Program of the Vall d’Hebron College Hospital’s (HUVH) Hematology Service, outcomes of a examine present that sufferers with refractory giant B-cell lymphoma (LBCL) who had acquired chimeric antigen receptor (CAR) T-cell remedy and therapy with bendamustine earlier than apheresis had a shorter progression-free survival and general response charge compared with the bendamustine-naïve group, regardless of affected person traits and dose acquired.
Bendamustine is a sort of chemotherapy referred to as an alkylating drug and is used within the therapy of power lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), and myeloma. Whereas scientific consensus pointers exist on the constraints of utilizing bendamustine because of its toxic effect on affected person lymphocytes, this multicenter examine—outcomes of which just lately printed within the Journal of Clinical Oncology—is the primary to report on the influence of latest publicity (9 months) to this agent as an unbiased issue of poorer outcomes of CAR-T cell remedy in sufferers with LBCL.
“Whereas the arrival of CAR T-Cell remedy has undoubtedly revolutionized the therapy panorama of sufferers with relapsed or refractory giant B-cell lymphoma, solely between 30% and 40% of sufferers infused with CAR T-cells obtain a sturdy remission,” says Gloria Iacoboni, Hematologist at HUVH, Medical Investigator of VHIO’s Experimental Hematology Group and first creator of this Authentic Report.
“Sufferers who progress after this remedy have low response charges to salvage regimens, and long-term outcomes are dismal. Advancing insights into components related to therapy success will finally assist us to enhance outcomes for extra of our sufferers,” provides Pere Barba, Director of the Superior Therapies Program of HUVH’s Hematology Service, Medical Investigator of the identical VHIO Group and corresponding creator of this text.
This retrospective examine included clinical data of 439 sufferers who had acquired CAR T-cell remedy within the third or later line of therapy at 7 European websites. These sufferers had been divided into two totally different cohorts based mostly on whether or not they had been uncovered to bendamustine previous to T-lymphocyte apheresis. Eighty (18%) sufferers had been uncovered to this agent at a median of 6 months earlier than T cell assortment with a median of 4 cycles of therapy.
After statistically equating baseline traits to rule out that the outcomes had been maybe influenced by the truth that these sufferers who had acquired bendamustine had extra aggressive illness, the investigators recognized earlier publicity as an unbiased issue related to poorer outcomes following CAR T-cell remedy.
In a second evaluation, they sought to verify if latest publicity (9 months earlier than apheresis) to bendamustine led to worse outcomes. Current publicity to this agent correlated with poorer outcomes, regardless of affected person traits and dose acquired. The 42 sufferers who had acquired this agent 9 months earlier than apheresis had a median overall survival of 4.6 months in comparison with 23.5 months within the bendamustine-naïve group.
“On the idea of our outcomes, the usage of bendamustine must be averted when attainable in sufferers with refractory giant B-cell lymphoma who’re potential candidates for CAR T-cell remedy,” observes Pere Barba.
“Our findings must be thought-about in future scientific pointers, not just for these lymphomas but in addition for different varieties of lymphoma which will ultimately progress and require CAR-T therapies, as we collectively search to anticipate all therapy eventualities and enhance affected person outcomes.”
Gloria Iacoboni et al, Current Bendamustine Therapy Earlier than Apheresis Has a Unfavorable Affect on Outcomes in Sufferers With Massive B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Remedy, Journal of Medical Oncology (2023). DOI: 10.1200/JCO.23.01097
Vall d’Hebron Institute of Oncology
Bendamustine previous to CAR T-cell remedy in sufferers with refractory giant B-cell lymphoma: Poorer therapy outcomes (2023, December 19)
retrieved 19 December 2023
This doc is topic to copyright. Aside from any truthful dealing for the aim of personal examine or analysis, no
half could also be reproduced with out the written permission. The content material is offered for data functions solely.